Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center

American Journal of Medicine

Volumn 113, Issue 6, 2002, Pages 472-479

  Waalen, Jill ^a   Felitti, Vincent ^b   Gelbart, Terri ^a   Ho, Ngoc J ^a   Beutler, Ernest ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Kaiser Permanente ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FERRITIN; IRON BINDING PROTEIN; TRANSFERRIN;

ADULT; ADULTHOOD; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; GENE; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HETEROZYGOSITY; HIGH RISK POPULATION; HOMEOSTASIS; HUMAN; IRON METABOLISM; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AGED; AGED, 80 AND OVER; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FERRITINS; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; IRON; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; RISK FACTORS; TRANSFERRIN;

EID: 0037109598     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01249-4     Document Type: Article

References (29)

1. Niederau C. Iron overload and atherosclerosis. Hepatology. 32:2000;672-674.
2. Corti M.C., Gaziano M., Hennekens C.H. Iron status and risk of cardiovascular disease. Ann Epidemiol. 7:1997;62-68.
3. de Valk B., Marx J.J.M. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med. 159:1999;1542-1548.
4. Sempos C.T., Looker A.C., Gillum R.F. Iron and heart disease the epidemiologic data. Nutr Rev. 54:1996;73-84.
5. Beutler E., Felitti V., Gelbart T., et al. The effect of HFE genotypes in patients attending a health appraisal clinic. Ann Intern Med. 133:2000;329-337.
6. Tuomainen T.P., Kontula K., Nyyssonen K., et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation a prospective cohort study in men in eastern Finland. Circulation. 100:1999;1274-1279.
7. Rasmussen M.L., Folsom A.R., Catellier D.J., et al. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 154:2001;739-746.
8. Roest M., van der Schouw Y.T., de Valk B., et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 100:1999;1268-1273.
9. Calado R.T., Franco R.F., Pazin A., et al. HFE gene mutations in coronary atherothrombotic disease. Braz J Med Biol Res. 33:2000;301-306.
10. Annichino-Bizzacchi J.M., Saad S.T., Arruda V.R., et al. C282Y mutation in the HLA-H gene is not a risk factor for patients with myocardial infarction. J Cardiovasc Risk. 7:2000;37-40.
11. Hetet G., Elbaz A., Gariepy J., et al. Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest. 31:2001;382-388.
12. Battiloro E., Ombres D., Pascale E., et al. Haemochromatosis gene mutations and risk of coronary artery disease. Eur J Hum Genet. 8:2000;389-392.
13. Franco R.F., Zago M.A., Trip M.D., et al. Prevalence of hereditary hemochromatosis in premature atherosclerotic vascular disease. Br J Haematol. 102:1998;1172-1175.
14. Nassar B.A., Zayed E.M., Title L.M., et al. Relation of HFE gene mutations, high iron stores and early onset coronary artery disease. Can J Cardiol. 14:1998;215-220.
15. Balan V., Baldus W., Fairbanks V., et al. Screening for hemochromatosis a cost-effectiveness study based on 12,258 patients. Gastroenterology. 107:1994;453-459.
16. Adams P.C., Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis evolution of diagnostic criteria. Gastroenterology. 114:1998;319-323.
17. Bassett M.L., Leggett B.A., Halliday J.W., et al. Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers. J Hepatol. 27:1997;517-524.
18. Beutler E., Gelbart T. Large-scale screening for HFE mutations methodology and cost. Genet Test. 4:2000;131-142.
19. Salonen J.T., Nyyssönen K., Korpela H., et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 86:1992;803-811.
20. Iribarren C., Sempos C.T., Eckfeldt J.H., et al. Lack of association between ferritin level and measures of LDL oxidation the ARIC study. Atherosclerosis Risk in Communities. Atherosclerosis. 139:1998;189-195.
21. Magnusson M.K., Sigfusson N., Sigvaldason H., et al. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation. 89:1994;102-108.
22. Sempos C.T., Looker A.C., Gillum R.F., Makuc D.M. Body iron stores and the risk of coronary heart disease. N Engl J Med. 330:1994;1119-1124.
23. Baer D.M., Tekawa I.S., Hurley L.B. Iron stores are not associated with acute myocardial infarction. Circulation. 89:1994;2915-2918.
24. Liao Y., Cooper R.S., McGee D.L. Iron status and coronary heart disease negative findings from the NHANES I epidemiologic follow-up study. Am J Epidemiol. 139:1994;704-712.
25. Giles W.H., Anda R.F., Williamson D.F., et al. Body iron stores and the risk of coronary heart disease. [letter] N Engl J Med. 331:1994;1159-1160.
26. Looker A.C., Johnson C.L. Prevalence of elevated serum transferrin saturation in adults in the United States. Ann Intern Med. 129:1998;940-945.
27. Mokdad A.H., Bowman B.A., Ford E.S., et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 286:2001;1195-1200.
28. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults findings from the Third National Health and Nutrition Examination Survey. JAMA. 287:2002;356-359.
29. Felitti V.J., Anda R.F., Nordenberg D., et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med. 14:1998;245-258.